A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-Sensitive Ovarian Cancer in First Relapse.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-Sensitive Ovarian Cancer in First Relapse.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Farletuzumab (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Eisai Co Ltd; Morphotek
  • Most Recent Events

    • 09 Aug 2017 This trial has been discontinued in Belgium, as per European Clinical Trials Database record.
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Subgroup analysis (n=468) of molecular and protein signatures on FAR serum levels, presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top